AHR and prostate cancer: Exposing a human prostate cancer cell line to the AHR agonists TCDD and/or benzo[a]pyrene (BaP) rapidly induced WNT5A expression and increased mRNA levels of FZD1, FZD3, and LEF1 (Table 1) [41].